304 related articles for article (PubMed ID: 29230472)
1. Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
Laiteerapong N; Cooper JM; Skandari MR; Clarke PM; Winn AN; Naylor RN; Huang ES
Ann Intern Med; 2018 Feb; 168(3):170-178. PubMed ID: 29230472
[TBL] [Abstract][Full Text] [Related]
2. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
[TBL] [Abstract][Full Text] [Related]
3. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
Vijan S; Sussman JB; Yudkin JS; Hayward RA
JAMA Intern Med; 2014 Aug; 174(8):1227-34. PubMed ID: 24979148
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
Hunt B; Mocarski M; Valentine WJ; Langer J
J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes.
Shao H; Laxy M; Gregg EW; Albright A; Zhang P
Value Health; 2021 Feb; 24(2):227-235. PubMed ID: 33518029
[TBL] [Abstract][Full Text] [Related]
7. Influence of Diabetes Complications on HbA
Shao H; Lin J; Zhuo X; Rolka DB; Gregg EW; Zhang P
Diabetes Care; 2019 Nov; 42(11):2136-2142. PubMed ID: 31530661
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
9. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
[TBL] [Abstract][Full Text] [Related]
10. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
[TBL] [Abstract][Full Text] [Related]
12. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
Samyshkin Y; Guillermin AL; Best JH; Brunell SC; Lloyd A
J Med Econ; 2012; 15 Suppl 2():6-13. PubMed ID: 22793669
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
[TBL] [Abstract][Full Text] [Related]
14. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
[TBL] [Abstract][Full Text] [Related]
15. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.
Sinha A; Rajan M; Hoerger T; Pogach L
Diabetes Care; 2010 Apr; 33(4):695-700. PubMed ID: 20056950
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Tunis SL; Sauriol L; Minshall ME
Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK.
Pollock RF; Muduma G; Valentine WJ
Diabetes Obes Metab; 2013 Feb; 15(2):121-9. PubMed ID: 22882321
[TBL] [Abstract][Full Text] [Related]
18. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
Valentine WJ; Tucker D; Palmer AJ; Minshall ME; Foos V; Silberman C;
Value Health; 2009; 12(1):1-9. PubMed ID: 18657104
[TBL] [Abstract][Full Text] [Related]
19. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]